The Director will lead activities related to Early Clinical Development (ECD) essential to the growth of Otsuka’s discovery and early phase pipeline within OPDC’s Early Development Organization (EDO). Reporting to the ECD Nephrology/Immunology (N/I) Therapeutic Area Head, this Director is a strategic scientific and clinical leader accountable for the end-to-end early clinical development strategy and execution for Otsuka's early phase portfolio, with emphasis on N/I indications, including but not limited to immunologic and inflammatory diseases in nephrology, rheumatology, immunology, and dermatology. The role shapes program strategy from indication selection through early clinical development (pre-IND through first-in-human and clinical proof of concept) and go/go no decisions based on clinical and/or biomarker driven endpoints ensuring seamless integration across discovery, nonclinical, clinical pharmacology, regulatory, and commercial functions. The Director, ECD – N/I, in alignm...